クイック注文

GM-CSF/CSF2  Protein, Antibody, ELISA Kit, cDNA Clone

製品の説明: Active  
発現宿主: Human Cells  
10015-H07H-500
10015-H07H-5
10015-H07H-20
10015-H07H-100
10015-H07H-1
500 µg 
5 µg 
20 µg 
100 µg 
1 mg 
Add to Cart
  • Slide 1
製品の説明: Active  
発現宿主: Human Cells  
10015-H01H-5
10015-H01H-20
10015-H01H-100
5 µg 
20 µg 
100 µg 
Add to Cart
  • Slide 1
発現宿主: Yeast  
10015-HNAY-500
10015-HNAY-5
10015-HNAY-20
10015-HNAY-100
10015-HNAY-1
500 µg 
5 µg 
20 µg 
100 µg 
1 mg 
Add to Cart
  • Slide 1
発現宿主: Human Cells  
10015-HNAH-5
10015-HNAH-20
10015-HNAH-100
5 µg 
20 µg 
100 µg 
Add to Cart
  • Slide 1
発現宿主: Human Cells  
51048-MNAH-50
51048-MNAH-20
50 µg 
20 µg 
Add to Cart
  • Slide 1
発現宿主: Human Cells  
51048-M07H-50
51048-M07H-20
50 µg 
20 µg 
Add to Cart
  • Slide 1
発現宿主: Human Cells  
51048-M01H-50
51048-M01H-20
50 µg 
20 µg 
Add to Cart
  • Slide 1
発現宿主: Human Cells  
80020-R07H-50
80020-R07H-20
50 µg 
20 µg 
Add to Cart
  • Slide 1
発現宿主: Human Cells  
80020-R01H-50
80020-R01H-20
50 µg 
20 µg 
Add to Cart
  • Slide 1

GM-CSF/CSF2 Related Area

GM-CSF/CSF2 関連経路

GM-CSF/CSF2 関連製品

GM-CSF/CSF2 サマリー & タンパク質情報

GM-CSF/CSF2 背景

遺伝子の概要: GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exit the circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer.
General information above from NCBI
サブユニット構造: Monomer. The signaling GM-CSF receptor complex is a dodecamer of two head-to-head hexamers of two alpha, two beta, and two ligand subunits. {ECO:0000269|PubMed:18692472}.
細胞内位置: Secreted.
シーケンスの類似性: Belongs to the GM-CSF family. {ECO:0000305}.
General information above from UniProt

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

GM-CSF/CSF2 代替名

GM-CSF/CSF2 関連研究

  • Robertson SA. (2007) GM-CSF regulation of embryo development and pregnancy. Cytokine Growth Factor Rev. 18(3-4): 287-98.
  • Waller EK. (2007) The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist. 12 Suppl 2: 22-6.
  • Clive KS, et al. (2010) Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines. 9(5): 519-25.
  • 注意:すべての製品は、"研究目的のみに使用するものであり、診断または治療目的に使用するものではありません"